# TGA

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/tga-organization
Canonical HTML page: https://getbiobrief.com/entity/tga-organization

## Timeline

- **2026-02**: TGA Approval — Australian regulatory body approves the Virtual Nodule Clinic for clinical use.
- **2022-09**: Series A Funding — Company raises $14M to scale its AI clinical platform globally.
- **2021-03**: FDA Clearance — Optellum receives first-of-its-kind FDA clearance for AI lung cancer decision support.

## Recent coverage (1 stories)

### Optellum Secures TGA Approval for AI Lung Cancer Solution in Australia
2026-02-27 02:36:24 · Sentiment: Positive · Impact: 7/10 · Sources: 3

Optellum has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. The approval enables the deployment of the Virtual Nodule Clinic to help Australian clinicians identify and treat early-stage lung cancer more effectively.
Full story: https://getbiobrief.com/story/optellum-tga-approval-lung-nodule-ai-australia

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.